Product Information
OXYBUTYNIN CL ER 15 MG TABLET is a generic product labeled by Chartwell RX LLC, priced at $0.1250 per EA under NDC 62135050990. Its NADAC has been published 169 times since Jul 12, 2023.
FDA first approved this application on Feb 4, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
15 mg/1
Manufacturer
Chartwell RX LLCNDC
62135050990
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXYBUTYNIN CHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078503FDA Approved
2/4/2009
TE Code
AB
On Market Since
3/1/2009
Pharmacological Classes
Price Statistics
The NADAC for OXYBUTYNIN CL ER 15 MG TABLET has been published 169 times since Jul 12, 2023, and over the history we have for it it has declined 21.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1250 per EA |
|---|---|
| All-time high | $0.1735 (Sep 13, 2023) |
| All-time low | $0.0936 (Apr 17, 2024) |
| 52-week high | $0.1268 |
| 52-week low | $0.1161 |
| Median price | $0.1301 |
| Average price | $0.1318 |
| Largest weekly change | +38.9% (May 22, 2024) |
| Weeks tracked | 169 |
| Tracking since | Jul 12, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the OXYBUTYNIN CHLORIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
OXYBUTYNIN CHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Muscarinic Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXYBUTYNIN CL ER 15 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OXYBUTYNIN CL ER 15 MG TABLET, manufactured by Chartwell RX LLC, is $0.1250 per EA (NDC 62135050990), effective Sep 30, 2026.
How has the price of OXYBUTYNIN CL ER 15 MG TABLET changed over time?
Over the history we have for it, the NADAC for OXYBUTYNIN CL ER 15 MG TABLET has declined 21.3%. It has been tracked across 169 weekly CMS publications since Jul 12, 2023.
What are the highest and lowest recorded NADAC prices for OXYBUTYNIN CL ER 15 MG TABLET?
Since Jul 12, 2023, the NADAC for OXYBUTYNIN CL ER 15 MG TABLET has ranged from a low of $0.0936 (Apr 17, 2024) to a high of $0.1735 (Sep 13, 2023), with a median of $0.1301 per EA.
Are there cheaper alternatives to OXYBUTYNIN CL ER 15 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of OXYBUTYNIN CL ER 15 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OXYBUTYNIN CL ER 15 MG TABLET?
OXYBUTYNIN CL ER 15 MG TABLET (NDC 62135050990) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.